B. Shah

发表

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

K. Bhalla, Y. Zu, Sunil Sharma, 2014, Leukemia.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

K. Bhalla, Sunil Sharma, D. Bearss, 2014, Leukemia.

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Michael L. Wang, K. Rajapakshe, C. Coarfa, 2015, Blood.

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Jenny C. Chang, A. Melnick, K. Bhalla, 2014, Oncotarget.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

K. Bhalla, D. Bearss, S. Iyer, 2017, Leukemia.

BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

J. Qi, J. Bradner, K. Bhalla, 2014, Molecular Cancer Therapeutics.

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

J. Qi, J. Bradner, J. Sheng, 2014, Molecular Cancer Therapeutics.

Highly active combination of BRD 4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia ( AML ) cells

J. Qi, J. Bradner, J. Sheng, 2013 .

Small Molecule Therapeutics BET Protein Antagonist JQ 1 Is Synergistically Lethal with FLT 3 Tyrosine Kinase Inhibitor ( TKI ) and Overcomes Resistance to FLT 3-TKI in AML Cells Expressing FLT-ITD

J. Qi, J. Bradner, K. Bhalla, 2014 .

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist

J. Qi, J. Bradner, K. Bhalla, 2015, Leukemia.